

RUTLAND HEALTH AND WELLBEING BOARD

12 JULY 2022

DRAFT PHARMACEUTICAL NEEDS ASSESSMENT 2022

Report of the Director of Public Health

Strategic Aim:	All	
Exempt Information	No	
Cabinet Member(s) Responsible:	Councillor Samantha Harvey: Portfolio Holder for Health, Wellbeing and Adult Care	
Contact Officer(s):	Andy Brown - Business Intelligence Team Leader	Telephone 0116 305 6096 email andy.brown@leics.gov.uk
	Mike Sandys, Director of Public Health	Telephone – 0116 3054239 email – mike@sandys@leics.gov.uk
Ward Councillors		

DECISION RECOMMENDATIONS

That the Committee:

1. Notes the work undertaken to produce the draft Pharmaceutical Needs Assessment (PNA) 2022, which has been developed in line with the findings of the public and pharmacy surveys.
2. Comments on the draft PNA which is now out for consultation, to inform the final document.
3. Notes that a further draft will be circulated to the Board prior to 1 October 2022 detailing the outcome of the consultation and seeking approval of the final PNA.

1. PURPOSE OF THE REPORT

- 1.1 The purpose of the report is to provide the Health and Wellbeing Board (HWB) with an update on work undertaken to produce the draft Rutland Pharmaceutical Needs Assessment (PNA) 2022 as a basis for consultation and to seek the Board's comments on the draft document.

2. BACKGROUND AND MAIN CONSIDERATIONS

- 2.1 The purpose of the PNA is to:

- identify the pharmaceutical services currently available and assess the need for pharmaceutical services in the future.

- inform the planning and commissioning of pharmacy services by identifying which services should be commissioned for local people, within available resources, and where these services should be.
 - inform decision making in response to applications made to NHS England by pharmacists and dispensing doctors to provide a new pharmacy. The organisation that will make these decisions is NHS England.
- 2.2 The last PNA for Rutland was produced in 2018 and can be accessed at: <https://www.lsro-online.org/pharmaceutical-needs-assessment1.html>
- 2.3 The PNA is a statutory document that is used by NHS England to agree changes to the commissioning of local pharmaceutical services. As such, if NHS England receives a legal challenge to the services that they commission based on the PNA, the local authority could also be part of that legal challenge. It is essential that the process that is followed meets the legislation that is set out and that the PNA is a robust document.
- 2.4 In October 2021, the Department of Health and Social Care published a pharmaceutical needs assessment information pack for local authority health and wellbeing boards to support in the developing and updating of PNAs. The PNA guidance can be accessed via the following link: <https://www.gov.uk/government/publications/pharmaceutical-needs-assessments-information-pack>
- 2.5 A PNA Reference Group has been established to oversee the detailed production of the PNA documents for Rutland as well as Leicester and Leicestershire to ensure a consistent local approach. Membership of this group includes - local authorities, NHS England, the Local Pharmaceutical Committee, Local Professional Network for Pharmacists and the Leicester, Leicestershire and Rutland Local Medical Committee, Clinical Commissioning Groups and Healthwatch. Although there is a common approach, there will be separate PNAs for Rutland, Leicester and Leicestershire.
- 2.6 The principal resourcing for the development of the Rutland PNA is provided by the Public Health Department and Business Intelligence Team, with information and advice provided through the PNA Project Team by NHS England, the Leicestershire Pharmaceutical Committee, CCGs and others.
- 3. CONTENT**
- 3.1 The regulations and guidance documents provide information on the PNA content. This has been reflected in the draft consultation PNA appended as Appendix A. A similar, though more streamlined, approach has been taken to that in the 2018 PNA, with more detailed information included in the supporting appendices.
- 3.2 Since the last PNA the Government's policy document of "Community pharmacy in 2016/17 and beyond" has been implemented. The impact of these changes and an assessment of the new and emergent system has been examined to understand the implications for the PNA 2022.
- 3.3 The PNA Reference Group considered pre-consultation drafts of the Rutland PNAs at its meeting on 26 April 2022. The document followed a similar but more streamlined format to the 2018 version, which met statutory requirements. The document has also been streamlined to reflect initial comments from the Rutland Board Chair on the draft. The views of the Reference Group were incorporated into the draft Rutland document

3.4 This draft includes analysis and presentation of available data and also the headline results from a survey of local pharmacies. In light of the relatively low response rate the survey has been re-opened, and the findings will be incorporated into the final PNA. The Appendices to the PNA form a lengthy addition to the report and hence have been included for reference in the link attached - https://www.lsr-online.org/uploads/32_62a1b0feeee1c475270077.pdf

4. CONSULTATION

4.1 To gather additional intelligence for the development of the draft PNA, two surveys ran throughout the spring. One survey asked service users for their views on the current pharmaceutical provision and the second gathered data on services provided, opening times etc from pharmaceutical professionals. The findings from these two survey exercises have been incorporated into the draft PNA document.

4.2 The PNA is subject to a 60-day statutory consultation period which commenced in June 2022. The Pharmaceutical Services Regulations specify that the Health and Wellbeing Board must consult with the following (and drafts have been issued to these bodies to commence the consultation process): -

- the Local Pharmaceutical Committee (LPC)
- the Local Medical Committee
- any persons on the pharmaceutical lists and any dispensing doctors list for its area
- any LPS chemist in its area with whom NHS England has made arrangements for the provision of any local pharmaceutical services
- Healthwatch, and any other patient, consumer or community group in its area which in the view of the Health and Wellbeing Board has an interest in the provision of pharmaceutical services in its area.
- any NHS trust or NHS foundation trust in its area
- NHS England
- any neighbouring HWB.

4.3 Health and Wellbeing Boards must consult the above at least once during the process of developing the PNA. Those being consulted have been directed to a website address containing the draft PNA and a survey for responses. They can, if they request, be sent an electronic or hard copy version.

4.4 The Reference Group has worked with the Consultation Manager to design an effective consultation process. The draft PNA has been published on the LSR Online website, with links to other sites - <https://www.leicestershire.gov.uk/have-your-say/current-engagement/draft-pharmaceutical-needs-assessment-2022> - and the views of the statutory consultees and other stakeholders are being actively sought. A summary version of the PNA has also been developed.

5. ALTERNATIVE OPTIONS

5.1 The PNA is a statutory document with guidance setting out what is expected to be included and in terms of timescales and the process to be followed. Though there is

some discretion in terms of how the final document is presented including the main document and appendices.

6. FINANCIAL IMPLICATIONS

6.1 Pharmacy Services are core funded through NHS England budgets, but also commissioned for extra services from a range of sources. Any changes in services and provision will impact on those particular budgets. The PNA has been developed within existing business intelligence and public health budgets, including the consultation arrangements.

7. LEGAL AND GOVERNANCE CONSIDERATIONS

7.1 The HWB has a statutory responsibility to prepare a PNA for Rutland and publish it by 1 October 2022. At a previous meeting, the Health and Wellbeing Board noted the timescales and process for the production of the PNA, along with areas of focus, likely structure, governance and consultation arrangements to inform the draft.

7.2 The NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 (amended) sets out the minimum information that must be contained within a PNA and outlines the process that must be followed in its development and can be found at: <https://www.legislation.gov.uk/uksi/2013/349/contents>

7.3 The project plan is tight with respect to delivering an approved PNA by 1 October 2022. The PNA Project Team will monitor this and report any issues of concern to the Health and Wellbeing Board. The current timescales are:

- July - consultation draft PNA submitted to the Health and Wellbeing Board for consideration and comments
- June – early August – formal 60-day consultation undertaken
- September – draft final PNA circulated to Health and Wellbeing Board for approval to publish
- 1 October 2022 – Publication of the PNA

8. DATA PROTECTION IMPLICATIONS

8.1 The surveys undertaken and data handled, which is aggregated and anonymised, has been done so in full compliance with data protection law and protocols.

9. EQUALITY IMPACT ASSESSMENT

9.1 An Equality Impact Assessment (EqIA) will be completed once the draft has been developed in light of the consultation process now underway. The draft PNA has looked to assess a number of equalities issues in terms of access to pharmacy services for different groups and language issues - these are set out in detail in the PNA. The consultation process is being targeted to a number of Equalities Groups.

10. COMMUNITY SAFETY IMPLICATIONS

10.1 None

11. HEALTH AND WELLBEING IMPLICATIONS

11.1 Pharmacy Services and access to them provide a cornerstone of services to support residents' health and wellbeing. The PNA looks at current services, resident health, health priorities and how services can be developed in the future

12. ORGANISATIONAL IMPLICATIONS

12.1 **Environmental Implications** - No major environmental implications

12.2 **Human Resource Implications** - The PNA highlights some pressure on existing pharmacy staff and the need for continued supply of the relevant trained workforce to maintain and develop existing provision.

12.3 **Procurement Implications** - The PNA informs commissioning and procurement of future pharmacy services.

13. CONCLUSION AND SUMMARY OF REASONS FOR THE RECOMMENDATIONS

13.1 The Rutland Health and Wellbeing Board needs to produce and agree a PNA in accordance with the necessary statutory guidance by 1 October 2022. The guidance sets out the process for production of a PNA including a 60-day period of statutory consultation on the draft. The Board is asked to comment on the current draft PNA document.

14. BACKGROUND PAPERS

14.1 Pharmaceutical Needs Assessment 2022 - Guidance and Information Pack

15. APPENDICES

15.1 Appendix A – Draft Rutland PNA 2022

Large Print or Braille Version of this Report is available upon request – Contact 01572 722577